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Abstract: “Nonallergic rhinopathy” was defined by consensus at a
Roundtable conference in December 2008 as “a chronic nasal
condition with symptoms that may be perennial, persistent, inter-
mittent or seasonal and/or elicited by recognized triggers.” The
definition includes a well-recognized set of clinical exposures that
lead to the symptoms, predominantly congestion, rhinorrhea, and
postnasal drip. These clinical characteristics help to identify patients
for participation in clinical trials examining the efficacy of treat-
ments for this important disease. The next step is to establish
inclusion and exclusion criteria that will provide a framework for the
clinical trials. Agreement on study criteria was obtained at the
consensus conference by discussion, counterpoint, and compromise.
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INTRODUCTION
To advance knowledge of a clinical entity, we must beginwith a definition. From this definition, we next design
clinical trials to study pathophysiology and/or examine ther-
apeutic options. The results of clinical trials help us to better
understand the disease, and might lead to refining the defini-
tion and the study parameters, notably the inclusion/exclusion
criteria.
As noted in previous articles in these Proceedings, the
medical literature contains various contradictory opinions
regarding the definition of vasomotor rhinitis (VMR) and its
pathophysiology, a fact that has complicated determination of
inclusion and exclusion criteria for clinical trials. In general,
expert opinion, guidelines, and published studies have sup-
ported a definition in which VMR subjects are described as
experiencing worsening rhinitis symptoms related to both
weather/temperature triggers (eg, changes in temperature,
barometric pressure, and humidity) and odor/irritant triggers
(eg, strong perfume, hot/spicy food, alcoholic beverages,
smoke, and other airborne irritants).1–9 The same clinical
description “by triggers” has been applied to nonallergic
rhinitis (NAR). There is only a clinical impression that these
triggers represent different disease processes, unsupported by
any pathophysiologic investigations.
Employing a definition based upon triggers alone may
be acceptable from a clinical practice standpoint, but it is
problematic from the perspective of developing appropriate
clinical trials to evaluate new treatment options. First, the
pathways by which the triggers cause nasal symptoms are not
clearly understood and may or may not differ. Second, there
are many stimuli which cause the spectrum of symptoms
clinically recognized as VMR, as illustrated in Table 1, which
shows the variety of opinions reported in the published
literature regarding factors that can result in a nasal vasomo-
tor response. Despite differences in the authors’ classifica-
tions of the response as NAR or VMR, it is evident that the
authors are describing the same symptomatic phenomena. In
most cases, the choice of the specific term (VMR or NAR)
seems arbitrary; and although VMR is often used in relation-
ship to weather or temperature change, the resulting symp-
toms overlap with those caused by other nonallergic stimuli.
As noted in the Consensus Definition from these Pro-
ceedings published in the June issue of the World Allergy
Organization journal the lack of straightforward diagnostic
criteria is limiting; research for better treatment options
requires the definition of “homogeneous” populations char-
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acterized by well-defined inclusion and exclusion criteria.
Based on expert opinion and review of the published litera-
ture, the attendees of the Roundtable proposed to revise the
terminology to reference this condition as “nonallergic rhi-
nopathy,” which they defined as “a chronic nasal condition
with symptoms that may be perennial, persistent, intermittent
or seasonal and/or elicited by recognized triggers.” Accord-
ing to this definition, the symptoms of nonallergic rhinopathy,
predominantly congestion, rhinorrhea, and postnasal drip,
may occur in response to a well-recognized set of clinical
exposures, may be associated with several comorbidities, and
can be distinguished from other well-defined clinical causes
of rhinopathy (see Part 1 of these Proceedings in the June
issue of this journal for greater detail). Those clinical char-
acteristics, as outlined in Table 2, can serve as the basis for
well-defined inclusion and exclusion criteria that should per-
mit precise identification of patients for participation in clin-
ical trials. As experience is gained from trials, these initial
starting criteria may need to be altered.
DISCUSSION AND CONSENSUS
Once the definition of nonallergic rhinopathy was
agreed upon, discussion at the Roundtable Meeting focused
on specific inclusion and exclusion criteria for study proto-
cols. Initially, it was suggested that to create a study to
evaluate the causes of, or potential treatment for, nonallergic
rhinopathy, each individual precipitating factor might need to
be investigated independently. In other words, the inclusion
and exclusion criteria for each study would reflect the specific
trigger of symptoms, and the trial endpoints would measure
the patient’s response to that particular trigger. Based on this
viewpoint, the duration of each study also would depend
upon the specific trigger. Weather/temperature triggers tend
to be more persistent than odor/irritant triggers; therefore,
TABLE 2. Clinical Characteristics of Nonallergic Rhinopathy
(Referred to in This Table as NAR)
Symptoms of NAR may be perennial, persistent, seasonal (i.e., seasonal
climatic changes–see below), intermittent and/or elicited by defined
triggers that may include:
• Cold air
• Changes in climate (temperature, humidity, barometric pressure)
• Strong smells (such as perfume, cooking smells, flowers, chemical
odors)
• Environmental tobacco smoke
• Changes in sexual hormones levels
• Pollutants and chemicals (e.g. volatile organics)
• Exercise
• Alcohol ingestion
NAR may present with concomitant conditions such as:
• Food-related rhinorrhea
• Mild nasal eosinophilia (5%)
• Eustachian tube dysfunction (ear pressure/popping/pain)
• Senile rhinitis
NAR symptoms are not caused by other known etiological causes for
rhinopathy, such as:
• Chronic rhinosinusitis or nasal polyps
• NARES (nasal eosinophilia 5%)
• Aspirin–related chronic rhinosinusitis, nasal polyps, or asthma
(although NAR is often seen as one of the clinical characteristics of
AERD)
• Infectious rhinitis or rhinosinusitis (e.g., viral upper respiratory
infections, bacterial/fungal rhinosinusitis, bacterial rhinitis)
• Anatomical abnormalities
• Drug usage, (e.g., adverse effect of systemic medication, excess use
of topical decongestants)
• Cerebrospinal fluid leak
• Pregnancy
TABLE 1. Triggers Included in Articles Describing Nonallergic (Vasomotor) Rhinitis
Paper Description o:p
Type of Triggers Included
Pollution Chemical Olfactory Temperature Weather Work-Related Food ETS
Bachert, 2004 (7) Review        
Banov et al, 2001 (10) Prospective study*        
Bonini et al, 2006 (11) Athletes  **    **  
Brandt and Bernstein, 2006 (1) Prospective study*        
Bousquet et al, 2008 (6) Review        
Ciprandi, 2004 (12) Review        
Garay, 2004 (13) Review        
Greiner and Meltzer, 2006 (14) Review        
Kaliner, 2007 (8) Review        
Molgaard et al, 2007 (15) Prospective study*        
Newhall and McGrath, 2004 (9) Review        
Rondon et al, 2007 (16) Prospective study*        
Settipane, 2001 (17) Review        
Webb et al, 2002 (18) Analysis of 3
pooled prospective studies*
       
Total for triggers 3 10 6 8 6 2 6 5
*Prospective trial in which nonallergic rhinitis was defined as symptoms from irritant triggers with negative allergy tests.
**Study of athletes: exercise-induced symptoms are listed as work-related in this table, and chemicals were swimming pool-related OK?
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studies involving the former would be of longer duration than
the latter. An example of a clinical study using weather-
related changes as the trigger was presented at the meeting to
illustrate these points.
Discussion, occasionally heated, followed this sug-
gested approach to the study design. Some participants dis-
agreed with the idea that 2 or more study designs are needed
for clinical studies of nonallergic rhinopathy; one for weather
and related triggers and another for the transient types of
triggers. This group stated that the range of triggers should be
included as entry criteria and not as endpoints, the endpoints
being changes in nasal symptoms and quality of life. In this
regard, the disease state (nonallergic rhinopathy) would be
treated like asthma for developing studies of new medications
to treat the clinical disease. Patients who are nonallergic and
who have appropriate chronic nasal symptoms, with no evi-
dence of mechanical obstruction or infectious disease, would
be studied using standardized, controlled protocols, regard-
less of the trigger. If their symptoms improve with statisti-
cally significant differences from placebo, then the outcome
is considered positive, and additional post hoc analyses/
stratification (eg, based on specific triggers, blood eosino-
phils, nasal secretions, and other possible stratifying criteria)
could also be performed. Other discussants emphasized that
not every clinical study of nonallergic rhinopathy study could
be performed in exactly the same manner. This group agreed
that simplifying the study design was needed but remained
concerned that including multiple triggers would introduce a
type 1 error. Furthermore, the group was nearly unanimous in
pointing out that nonallergic patients who have no recognized
triggers represent a legitimate portion of the nonallergic
rhinopathy population.
It was eventually agreed that the objective of this
consensus paper is how to design a study that is inclusive of
all patients with nonallergic rhinopathy to develop new ther-
apies. In this regard, then, it is not necessary to stratify
patients based on each specific trigger. Consensus was
achieved on the following.
Y In terms of efficacy protocols, triggers represent an
inclusion criteria and not a specific outcome. However,
triggers could be evaluated by post hoc subgroup anal-
ysis, as appropriate.
Y The endpoints of these studies are symptom score de-
pendent and should include the total nasal symptom
score, the individual nasal symptoms, and a quality of
life instrument such as the Rhinosinusitis Disability
Index, The Sino-nasal Outcomes Test, or the Rhinocon-
junctivitis Quality of Life Questionnaire.
Y Challenge studies with specific triggers such as might be
examined in chamber studies are not included in this
discussion and represent a separate entity in which the
trigger-induced symptoms might be evaluated as pri-
mary endpoints.
Y The inclusion criteria should be based on the character-
istics identified in the consensus definition of nonaller-
gic rhinopathy as shown in Table 2.
TABLE 3. Proposed Consensus Criteria for an Efficacy Study
of Therapy for Nonallergic Rhinopathy (Referred to in This
Table as NAR).
Inclusion: Subjects should meet all criteria listed below:
1. Diagnosis of non-allergic rhinopathy (NAR) as defined to include all
of the following:
a. Two year clinical history of NAR symptoms, including nasal
congestion, nasal discharge, and post-nasal drip
b. Chronic, perennial nature of symptoms with fluctuation/exacerbation
related to one or more triggers including: cold air, changes in climate
(temperature, humidity, barometric pressure), strong smells (such as
perfume, cooking smells, flowers, chemical odors), exposure to
environmental tobacco smoke, changes in sexual hormones levels,
exposure to pollutants and chemicals (e.g. volatile organics), abnormal
nasal response to exercise or alcohol ingestion.
c. Negative skin prick tests to seasonal allergens (e.g., trees, grass,
weed, etc) and perennial allergens (e.g., animal dander, house dust
mite, cockroach, etc). Negative test defined as a wheal 3mm
larger than the diluent control or negative serum specific IgE
antibody levels.
d. Positive response to histamine skin prick test. Positive test defined
as wheal 3 mm larger than the diluent control.
e. Normal sinus radiograph (Waters view or CT) to rule out sinusitis
2. Nasal cytology negative for eosinophils to rule out NARES (less than
5% of total cells)
3. Informed consent: Appropriately signed and dated informed consent for
study subjects ages 18 years and older. For study subjects ages less than
18 years, informed consent signed by parents or care providers
4. Subjects are able, willing, and likely to comply with study procedures
and restrictions
5. Subjects can be treated on outpatient basis
6. Age 12 years or older
7. Female of childbearing potential must commit to using acceptable
method of birth control [method may vary depending on marketing
status and teratogenicity potential]
8. Subjects literate enough to read, understand, and record information in
native language (or language that will be used in the study procedure)
Exclusion: Subjects will not be eligible for inclusion if any of the
following criteria is met:
1. Significant concomitant medical condition defined as but not limited to:
a. History or current evidence of clinically significant disease of
any body system that in the opinion of the investigator would
put the safety of the study subjects at risk through participation
in the study, or would confound the interpretation of the study
results.
b. Significant anatomical nasal disease such as physical obstruction
of the nose, substantial deviated nasal septum, or nasal septal
perforation that could affect the deposition of intranasal study
drug and interfere with interpretation of medication outcomes.
Rhinitis medicamentosa
c. Common cold or any bacterial or viral infection of the upper
respiratory tract for 14 days prior to screening period
d. Documented acute or chronic sinusitis, as determined by Waters
view or CT scan
e. Physical impairment that would affect subject’s participation in the
study
f. History of psychiatric disease, intellectual deficiency, poor
motivation, substance abuse, alcohol abuse, cocaine use, or other
conditions that would limit the validity of the informed consent, or
confound the interpretation of the study
g. Use of intranasal, inhaled, oral, intravenous, intramuscular,
ocular, or dermatologic corticosteroid for 30 days prior to
screening period
Continued
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Y Post hoc evaluation may be appropriate to assess indi-
vidual triggers and/or concomitant conditions (eg, gus-
tatory rhinitis).
Y Patients with chronic nonallergic rhinopathy without
triggers would not be included in these initial studies,
but the group recognized that nonallergic rhinopathy
without triggers is a part of the spectrum of nonaller-
gic rhinopathy and that it would be appropriate to
develop other clinical protocols in which the lack of
triggers is part of the inclusion/exclusion criteria.
Y The group agreed that nonallergic rhinopathy with nasal
eosinophilia (NARES) may well be a different patho-
physiologic entity. Until the relationship between non-
allergic rhinopathy and NARES are clearly established,
the group felt that nasal eosinophilia would be an ex-
clusion criteria, and those patients with NARES should
be studied in separate protocols.
In summary, the essential characteristics for inclusion
in clinical trials of nonallergic rhinopathy are: 1) no allergic
rhinitis; 2) negative prick skin tests or serum antigen specific
IgE assays; and 3) a series of symptoms, in a patient with
nonmechanical, noninfectious rhinitis.
Table 3 presents the entry criteria for an efficacy study
protocol for nonallergic rhinopathy based on the above con-
sensus points. For the purpose of listing inclusion and exclu-
sion criteria, it is assumed that the clinical study will be a
typical blinded, repeat dosing, parallel group or crossover,
outpatient study. The study should include a run-in period
long enough to establish that the subjects met a specific level
of nasal symptomatology (1–4 weeks) followed by a 2–4-
week treatment period. Exacerbations of the patient’s symp-
toms would be collected in the daily diary, and specific
triggers associated with the exacerbation would be recorded
before the study and during the study for possible post hoc
evaluation of specific triggers. However, in counterpoint, it
was noted that many of these patients already try to avoid
their triggers as much as they can, so it was not clear that
collecting data on exacerbations would be helpful. Significant
error could result from problems with poor recall and nega-
tive memory of an aversive stimulus. As such, the use of
objective instruments for quantifying the degree of symptoms
is preferred.
CONCLUSIONS
The Consensus group appreciated the importance of
nonallergic rhinopathy as a clinical disease in the US and
worldwide.6,17 Currently, there are no phase 3 trials in the US
examining treatment of this disease despite the interest on the
part of the pharmaceutical industry and the need by patients
for additional treatment options. The Consensus conference
was developed with the expectations that 1) an acceptable
definition of the disease could be established; 2) creation of
appropriate exclusion/inclusion criteria could be based on the
new definition; and 3) straightforward criteria will then lead
to new interest and the development of more studies in this
area. We believe that the criteria published in this paper,
taken in the context of the accompanying papers, will facil-
itate this development and lead to the availability of new
clinical choices for treatment of this disease. We also believe
that the process of consensus development can be useful for
other entities where clarity is needed.
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